Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895856 | 0.84 | S1PR3 (0.43) | AKR1C3AKR1C2S1PR3S1PR1 | |
| SCHEMBL940332 | 0.75 | MAPK1 (0.40) | L3MBTL1LMNABCHELIPES1PR3 | |
| SCHEMBL895866 | 0.74 | KCNQ2 (0.42) | LMNAAKR1C3AKR1C2S1PR3S1PR1 | |
| SCHEMBL22193246 | 0.74 | CRHR1 (0.40) | L3MBTL1LMNABCHELIPECRHR1 | |
| SCHEMBL896209 | 0.73 | MEN1 (0.56) | L3MBTL1LMNABCHELIPES1PR3 | |
| SCHEMBL22530887 | 0.71 | KMT2A (0.46) | L3MBTL1LMNAS1PR3S1PR1MAPK1 | |
| SCHEMBL896359 | 0.71 | AKR1C3 (0.38) | LMNAAKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL29355151 | 0.71 | KMT2A (0.46) | L3MBTL1LMNAS1PR3S1PR1MAPK1 | |
| SCHEMBL3430128 | 0.71 | S1PR3 (0.40) | L3MBTL1LMNAS1PR3S1PR1MAPK1 | |
| SCHEMBL896777 | 0.71 | AKR1C3 (0.44) | AKR1C3AKR1C2AKR1C1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | L3MBTL1 3783/4885LMNA 2869/4885AKR1C3 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.